Moderna, Inc. filings document the regulatory, financial and governance record of a commercial-stage mRNA biotechnology company. Form 8-K reports cover operating results, Regulation FD updates, FDA communications for investigational vaccine submissions, material agreements, patent-litigation settlements and financing arrangements tied to the company's vaccine and therapeutic portfolio.
Proxy and annual-meeting filings disclose board elections, shareholder voting results, executive compensation and governance provisions, including bylaw amendments. The filings also record capital-structure matters such as credit facilities, risk and disclosure controls around pipeline development, and formal updates related to products including Spikevax, mRESVIA, mNEXSPIKE and mCOMBRIAX.
Moderna, Inc. Chief Financial Officer James M. Mock reported routine equity compensation activity involving restricted stock units. On May 27-28, 1,101 restricted stock units were exercised and converted into an equal number of common shares. To cover tax obligations on these vests, 533 common shares were withheld at prices of $47.03 and $47.61 per share, rather than sold on the open market. Following these transactions, Mock directly holds 58,316 shares of Moderna common stock, along with additional unvested restricted stock units.
Moderna, Inc.’s Chief Legal Officer Shannon Thyme Klinger reported routine equity compensation activity involving restricted stock units (RSUs). On May 27 and 28, 2026, RSUs converted into a total of 1,101 shares of common stock, reflecting scheduled vesting of prior awards.
Across the same two days, 533 shares of common stock were disposed of at prices of $47.03 and $47.61 per share, solely to satisfy tax withholding obligations associated with the RSU vests. These transactions are not open-market purchases or sales and leave Klinger with a continuing direct ownership stake in Moderna common stock.
Moderna, Inc. President Stephen Hoge reported routine equity compensation activity involving restricted stock units (RSUs) and related tax withholding. On May 27 and May 28, 2026, RSUs converted into a total of 2,047 shares of common stock, reflecting vesting of prior awards.
To cover tax obligations on these vestings, a total of 990 common shares were withheld at prices of $47.03 and $47.61 per share, categorized as tax-withholding dispositions rather than open-market sales. Following these transactions, Hoge directly held about 1,479,054 shares of Moderna common stock. The filing also reports 151,933 shares held by a trust for the benefit of his spouse and children and 4,116 shares held by Valhalla, LLC as indirect holdings, with beneficial ownership of the trust shares disclaimed except for any pecuniary interest.
Moderna, Inc. insider-related entities reported an option exercise and share sale. On May 21, 2026, Flagship Pioneering, LLC exercised stock options to acquire 9,263 shares of Moderna common stock at $19.15 per share, from options that were fully vested and set to expire on August 10, 2026.
That same day, Flagship Pioneering conducted an open-market sale of 9,263 shares of common stock at an average price of $46.84 per share, leaving 3,924 shares of common stock held indirectly by Flagship Pioneering afterward. The filing also shows 2,224,015 shares held directly by Noubar Afeyan and additional indirect holdings of 747,897 shares by Flagship Ventures Fund IV-Rx, L.P. and 3,880,328 shares by Flagship Ventures Fund IV, L.P. The reporting person is the ultimate control person of these entities and disclaims beneficial ownership except to the extent of his pecuniary interest.
Moderna, Inc. President Stephen Hoge reported an exercise-and-sale transaction in company stock. On May 15, 2026, he exercised stock options to acquire a total of 53,336 shares of common stock at an exercise price of $19.15 per share and sold 53,336 shares of common stock at an average price of $48.40 per share in open-market transactions. The filing notes that the reported transaction was carried out under a pre-arranged Rule 10b5-1 trading plan adopted on November 13, 2025. After these transactions, Hoge directly held 1,477,997 shares of Moderna common stock, along with additional indirect holdings of 151,933 shares held by a family trust and 4,116 shares held through Valhalla, LLC.
Moderna, Inc. filing a Rule 144 notice regarding the proposed sale of 53,336 shares of Common Stock through Fidelity Brokerage Services on 05/15/2026. The excerpt also records a prior sale by Stephen Hoge of 160,009 shares on 02/23/2026, with cash considerations shown.
Moderna, Inc. reported governance updates from its May 6, 2026 board actions and annual stockholder meeting. The board amended the company’s Second Amended and Restated By-Laws to designate the federal district courts of the United States as the exclusive forum for Securities Act of 1933 claims, unless the company agrees otherwise in writing.
At the 2026 Annual Meeting, stockholders elected Class II directors Sandra Horning, M.D. and Abbas Hussain for three-year terms. Stockholders also approved, on a non-binding advisory basis, the compensation of the named executive officers and voted to hold future say-on-pay votes every year. In addition, stockholders ratified the appointment of Ernst & Young LLP as independent registered public accounting firm for the year ending December 31, 2026.
Moderna, Inc. director David M. Rubenstein reported new equity awards. On May 6, 2026, he received 2,092 restricted stock units, each convertible into one share of common stock.
He was also granted 9,681 stock options with an exercise price of $48.79 per share, expiring on May 6, 2036. Both the RSUs and options vest in full on the earlier of May 6, 2027 or Moderna's next Annual Meeting of Shareholders, subject to his continued service.
Moderna, Inc. director Hussain Abbas received a grant of 8,371 restricted stock units on May 6, 2026 as equity compensation. These restricted stock units convert into common stock on a one-for-one basis. The award will vest in full on the earlier of May 6, 2027, or Moderna's next Annual Meeting of Shareholders, subject to his continued service.